SK Bioscience Joins U.S.-Backed Ebola Project
The U.S. government is set to invest substantial funding in South Korea’s vaccine manufacturing capacity to respond to emerging pandemic threats.SK bioscience said on Oct. 29 that it will participate in an Ebola vaccine project receiving up to $99 million (about 131.0 billion won) in support from th
SK Bioscience has joined a U.S.-backed Ebola vaccine project that has received up to $99 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) under the Department of Health and Human Services. The project, led by the International AIDS Vaccine Initiative (IAVI) and Hilleman Laboratories, aims to develop a vaccine that can rapidly induce immunity with a single dose for the Bundibugyo virus, which has been spreading mainly in the Democratic Republic of the Congo.
SK Bioscience will be responsible for process scale-up and mass production of the vaccine, utilizing its German subsidiary IDT Biologika for drug product process from aseptic filling through final product manufacturing.
Brief written by urgent.news from BusinessKorea's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
